Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7389-LF Plus Nivolumab in Solid Tumors
NCT04078295Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2019
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in solid tumor, gastric cancer (GC), esophageal cancer, small cell lung cancer (SCLC), sponsored by Eisai Co., Ltd.. Started Sep 2019; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
solid tumorgastric cancer (GC)esophageal cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04078295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04078295.